Targeting TLR Signaling Cascades in Systemic Lupus Erythematosus and Rheumatoid Arthritis: An Update

Bibliographic Details
Title: Targeting TLR Signaling Cascades in Systemic Lupus Erythematosus and Rheumatoid Arthritis: An Update
Authors: George D. Kalliolias, Efthimia K. Basdra, Athanasios G. Papavassiliou
Source: Biomedicines, Vol 12, Iss 1, p 138 (2024)
Publisher Information: MDPI AG, 2024.
Publication Year: 2024
Collection: LCC:Biology (General)
Subject Terms: systemic lupus erythematosus, rheumatoid arthritis, Toll-like receptors, endosomal TLRs, TLR4, TLR antagonists, Biology (General), QH301-705.5
More Details: Evidence from animal models and human genetics implicates Toll-like Receptors (TLRs) in the pathogenesis of Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). Endosomal TLRs sensing nucleic acids were proposed to induce lupus-promoting signaling in dendritic cells, B cells, monocytes, and macrophages. Ligation of TLR4 in synovial macrophages and fibroblast-like synoviocytes (FLSs) by endogenous ligands was suggested to induce local production of mediators that amplify RA synovitis. Inhibition of TLRs using antagonists or monoclonal antibodies (mAbs) that selectively prevent extracellular or endosomal TLR ligation has emerged as an attractive treatment strategy for SLE and RA. Despite the consistent success of selective inhibition of TLR ligation in animal models, DV-1179 (dual TLR7/9 antagonist) failed to achieve pharmacodynamic effectiveness in SLE, and NI-0101 (mAb against TLR4) failed to improve arthritis in RA. Synergistic cooperation between TLRs and functional redundancy in human diseases may require pharmacologic targeting of intracellular molecules that integrate signaling downstream of multiple TLRs. Small molecules inhibiting shared kinases involved in TLR signaling and peptidomimetics disrupting the assembly of common signalosomes (“Myddosome”) are under development. Targeted degraders (proteolysis-targeting chimeras (PROTACs)) of intracellular molecules involved in TLR signaling are a new class of TLR inhibitors with promising preliminary data awaiting further clinical validation.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 12010138
2227-9059
Relation: https://www.mdpi.com/2227-9059/12/1/138; https://doaj.org/toc/2227-9059
DOI: 10.3390/biomedicines12010138
Access URL: https://doaj.org/article/f0fee9a00f4d40208050b4e0b3ac84a6
Accession Number: edsdoj.f0fee9a00f4d40208050b4e0b3ac84a6
Database: Directory of Open Access Journals
More Details
ISSN:12010138
22279059
DOI:10.3390/biomedicines12010138
Published in:Biomedicines
Language:English